Today, a Director at EKSO BIONICS (NASDAQ: EKSO), Steven Sherman, bought shares of EKSO for $300K.
Following this transaction Steven Sherman’s holding in the company was increased by 198.36% to a total of $601.2K.
See today’s analyst top recommended stocks >>
Based on EKSO BIONICS’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $2.52 million and GAAP net loss of $7.9 million. In comparison, last year the company earned revenue of $1.44 million and had a GAAP net loss of $8.3 million. Currently, EKSO BIONICS has an average volume of 117.2K.
Starting in March 2015, EKSO received 8 Buy ratings in a row. Four different firms, including B.Riley FBR and Sterne Agee CRT, currently also have a Buy rating on the stock.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ekso Bionics Holdings, Inc. engages in the design, development and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. It operates through the following segments: Medical Devices, Industrial Sales, and Engineering Services.
